Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9HD47
UPID:
MOG1_HUMAN
Alternative names:
Ran-binding protein MOG1
Alternative UPACC:
Q9HD47; D3DTR6; Q68DI3; Q9BR68; Q9HD48; Q9NRU9; Q9P001; Q9P0P2
Background:
The Ran guanine nucleotide release factor, also known as Ran-binding protein MOG1, plays a crucial role in cellular processes. It regulates intracellular trafficking of RAN, promotes guanine nucleotide release from RAN, and inhibits GTP binding. This protein is pivotal in maintaining GTP-bound RAN levels in the nucleus, influencing mitotic spindle dynamics. Additionally, it enhances SCN5A expression in cardiomyocytes, impacting heart muscle cell function.
Therapeutic significance:
Understanding the role of Ran guanine nucleotide release factor could open doors to potential therapeutic strategies.